LHX:NYSE
L3Harris Technologies, Inc.
Data as of 2026-03-10 - not real-time
$371.26
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
L3Harris (LHX) is trading at $371.26, just shy of its 52‑week high of $379.23, and sits comfortably above its 20‑day ($355.91), 50‑day ($342.17) and 200‑day ($291.29) SMAs, signaling a strong bullish trend. The RSI at 60.5 and a bullish MACD crossover (histogram +0.51) together with rising volume underscore continued upward momentum, while the stock currently respects a support zone near $329.28 and faces resistance around $379.23, offering a modest upside of roughly 4.5% per the DCF model. Recent material news – a $400 M THAAD interceptor contract and the appointment of Kenneth Sharp as CFO – adds concrete demand‑side catalysts that could sustain price appreciation in the near term.
Fundamentally, LHX posted $21.87 B in revenue with 2.3% YoY growth, solid operating (12.9%) and profit margins (7.3%), and generates robust free cash flow (~$2.73 B). The company pays a 1.35% dividend with a 56% payout ratio, suggesting dividend sustainability, but its forward PE of 27.3 and trailing PE of 43.5 are well above the industry average of 29.5, and a DCF fair value of $164.85 points to significant overvaluation despite strong cash generation and defensive sector tailwinds.
Fundamentally, LHX posted $21.87 B in revenue with 2.3% YoY growth, solid operating (12.9%) and profit margins (7.3%), and generates robust free cash flow (~$2.73 B). The company pays a 1.35% dividend with a 56% payout ratio, suggesting dividend sustainability, but its forward PE of 27.3 and trailing PE of 43.5 are well above the industry average of 29.5, and a DCF fair value of $164.85 points to significant overvaluation despite strong cash generation and defensive sector tailwinds.
Trading Recommendations
Short Term
< 1 yearhold
Conviction: 7/10
Key Factors
- Bullish technical indicators (SMA alignment, RSI, MACD)
- Recent large defense contract (THAAD)
- Proximity to resistance limiting near‑term upside
Medium Term
1–3 yearsbuy
Conviction: 8/10
Key Factors
- Steady earnings growth and strong free cash flow
- Attractive dividend yield with sustainable payout
- Projected upside of ~4.5% toward analyst target median of $390
Long Term
> 3 yearshold
Conviction: 7/10
Key Factors
- Long‑term defense spending tailwinds
- Consistent dividend income
- High valuation relative to fundamentals may cap long‑run returns
Key Metrics & Analysis
Financial Health
Revenue Growth2.30%
Profit Margin7.34%
P/E Ratio43.5
ROE8.19%
ROA4.23%
Debt/Equity60.61
P/B Ratio3.5
Op. Cash Flow$3.1B
Free Cash Flow$2.7B
Industry P/E29.5
Technical Analysis
TrendBullish
RSI60.5
Support$329.28
Resistance$379.23
MA 20$355.91
MA 50$342.17
MA 200$291.29
MACDBullish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$164.85
Target Price$388.11
Upside/Downside4.54%
GradeOvervalued
TypeGrowth
Dividend Yield1.35%
Risk Assessment
Beta0.47
Volatility33.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.